Vertex Pharmaceuticals, Inc.

Bristol-myers Squibb Compnay

Bristol-myers Squibb Pharma Company

Jinglan Zhou

Mark Thomas Miller

Jason McCartney

Sara Sabina Hadida Ruah

Brian Richard Bear

Fredrick Van Goor

Peter D J Grootenhuis

Peter Grootenhuis

Sara Sabina Hadida-Ruah

Corey Don Anderson

Thomas Cleveland

Jeremy J Clemens

Peter Diederik Jan Grootenhuis

Bryan A Frieman

Vijayalaksmi Arumugam

Johnny Uy

Andreas Peter Termin

Timothy Richard Coon

Haripada Khatuya

Prasuna Paraselli

Anna Hazlewood

Hayley Marie Binch

Paul Krenitsky

Fabrice Jean Denis Pierre

Matthew Michael Hamilton

Pramod Virupax Joshi

Alina Silina

Mehdi Michel Djamel Numa

Xiaoqing Yang

Vito Melillo

Alexander Russell Abela

Lev T D Fanning

Ashvani Singh

Raymond Stanley Gross

Fabrice Pierre

Sara Hadida Ruah

Sara E Swift

Minson Baek

Mehdi Michel Jamel Numa

Dean P Stamos

Timothy Donald Neubert

David Andrew Siesel

Urvi Jagdishbhai Sheth

Dennis James Hurley

Robert Michael Hughes

Ali Keshavarz-Shokri

Yi Shi

Gulin Erdogan Marelius

Paul Angell

Muna Shrestha

Esther Martinborough

Dean Wilson

Beili Zhang

Aarti Sameer Kawatkar

Tara Whitney

Brett Bradley Busch

Danielle Lehsten

Nicole Hilgraf

Michael P Deninno

Kathy Stavropoulos

Lori Ann Ferris

Mehdi Numa

Tara Leanne Hampton

Ronald Marcellus Knegtel

Mimi Lifen Quan

Steven John Durrant

Joanne Louise Pinder

Michael Edward O'Donnell

Benjamin Joseph Littler

John E Cochran

Jon J Hangeland

Michel Gallant

David Matthew Shaw

Claudio F Sturino

Nadia M Ahmad

Ales Medek

Brett C Bookser

Martyn Botfield

Stephen Andrew Thomson

Thumkunta Jagadeeswar Reddy

Joseph Pontillo

Anisa Nizarali Virani

Yeeman K Ramtohul

Weichao George Chen

Rajendran Vairagoundar

Michael Waldo

Cailan Wang

Yvonne Schmidt

Lidio Marx Carvalho Meireles

Kevin Gagnon

Edward Adam Kallel

Robert Pullin

Xin Gu

Nicole Zimmermann

Sunny Abraham

Lev Tyler Dewey Fanning

Lino J Valdez

Michael Paul DeNinno

Joe Anh Tran

Xu Bai

Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.

Cystic fibrosis transmembrane conductance regulator modulating agents

Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ('ABC') transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Indole derivatives as CFTR modulators

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

Modulators of cystic fibrosis transmembrane conductance regulator

Crystalline forms of Compound I: pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Crystalline forms of CFTR modulators

Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R, R, R, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.

Process of making CFTR modulators

Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ('ABC') transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ('CFTR'). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Modulators of ATP-binding cassette transporters

The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof. 

Growing community of inventors

San Diego, CA, United States of America

Jinglan Zhou